5mg Chewable Tablets for Dogs: Effective Pimobendan Pet Medicine

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Pimobendan
• Model NO.: 5mg Pimobendan Chewable Tablets for Dogs
• Type: The First Class
• Pharmacodynamic Influential Factors: Incompatibility
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 180477183
• Transport Package: Bottled
• Specification: 5mg/tablet
• Trademark: pinpaw
• Origin: Changsha
• Production Capacity: 50000 Boxes Per Day

Product Description

Product Description
GENERIC NAME:
Pimobendan Chewable Tablet
MAIN COMPONENT:
Pimobendan
DESCRIPTION:
Introducing our light brown, scrumptious beef-flavored tablet, designed specifically for dogs. Crafted with precision, each tablet features score lines on both sides for easy administration, ensuring your pet receives the right dose every time.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics: Pimobendan is a powerful, non-glycoside cardiotonic medication. This wonder drug belongs to the benzimidazole pyridazinone derivative class and functions as a non-sympathomimetic, non-glycoside positive inotropic compound. It enhances heart muscle contraction by increasing calcium sensitivity and inhibiting phosphodiesterase (Type III) activity. Additionally, it offers vasodilating properties by reducing phosphodiesterase activity. When combined with diuretics like furosemide, pimobendan significantly improves life quality and extends life expectancy for dogs suffering from dilated cardiomyopathy or heart valve insufficiency. Additionally, when administered to large breed dogs with asymptomatic preclinical dilated cardiomyopathy, it delays heart failure onset or sudden death, markedly improving survival.
Pimobendan ingeniously reduces heart volume in dogs with preclinical myxomatous mitral valve disease, characterized by a systolic mitral murmur and increased heart size. Remarkably, it postpones clinical signs of heart failure or sudden cardiac death by up to 15 months, while enhancing overall survival by around 170 days.
Pharmacokinetics: Pimobendan undergoes oxidative demethylation in the body to create an active metabolite, which conjugates with sulfate or glucuronide and is primarily excreted in feces. The protein binding of pimobendan and its active metabolite in canine plasma exceeds 90%, demonstrating its strong affinity.
A comprehensive bioequivalence study was performed comparing our product to the reference Pimobendan Chewable Tablet (Vetmedin^®). The findings conclusively show bioequivalence, ensuring our product meets the highest standards.
INDICATIONS:
This remarkable product is your go-to solution for managing congestive cardiac failure (CCF) in dogs due to heart valve insufficiencies like mitral or tricuspid regurgitation, or in cases of dilated cardiomyopathy. It's also invaluable for large dogs with preclinical dilated cardiomyopathy, identified by increased left ventricular dimensions. Additionally, it aids in managing preclinical myxomatous mitral valve disease, characterized by a systolic murmur and heart enlargement, delaying CCF's clinical progression.
DOSAGE AND ADMINISTRATION:
For optimal results, administer an oral dose calculated on the basis of pimobendan: 0.25 mg per kilogram of the dog's body weight, administered twice daily.
ADVERSE REACTIONS:
1. Some dogs may exhibit a slight increase in heart rate (positively chronotropic effect) and occasional vomiting, which are generally mild and dose-dependent, often resolving spontaneously with dosage adjustment. Transient symptoms like diarrhea, anorexia, or lethargy might also present in a small subset of dogs.
2. While a direct connection with pimobendan remains unconfirmed, a minuscule fraction of dogs may exhibit signs related to primary haemostasis, such as mucosal or subcutaneous hemorrhages, during treatment. These symptoms generally vanish naturally once the treatment is halted.
3. In exceptionally rare circumstances, there may be an escalation in mitral regurgitation during the administration of pimobendan in canines suffering from mitral valve disease.
PRECAUTIONS:
1. Refrain from using this product in cases of hypertrophic cardiomyopathies or where cardiac output cannot be enhanced due to functional or anatomical reasons, like aortic stenosis. As the product is predominantly processed through the liver, it is not recommended for dogs with severe liver failure.
2. This product's efficacy has not been evaluated in asymptomatic dilated cardiomyopathy (DCM) cases in Dobermans that also have atrial fibrillation or sustained ventricular tachycardia.
3. The product has not undergone testing in asymptomatic myxomatous mitral valve disease in dogs showing pronounced supraventricular or ventricular tachyarrhythmia.
4. In laboratory studies involving rats and rabbits, no teratogenic or foetotoxic effects were recorded. However, these studies did reveal maternotoxic and embryotoxic effects at high doses and demonstrated that the drug is excreted in milk. The safety of this product in pregnant or nursing bitches has not been evaluated. Use only based on a thorough benefit/risk assessment by the veterinarian responsible.
5. During treatment, it is essential to conduct regular blood glucose tests in dogs already diagnosed with diabetes mellitus.
6. For the 'preclinical stage' of dilated cardiomyopathy (asymptomatic with increased left ventricular end-systolic and end-diastolic diameter), a comprehensive cardiac examination, including echocardiography and ambulatory ECG monitoring, is vital for accurate diagnosis.
7. In preclinical myxomatous mitral valve disease (stage B2, as per ACVIM consensus: asymptomatic with a mitral murmur ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), a comprehensive cardiac examination, including echocardiography and radiography, is necessary for proper diagnosis.
8. It is advisable to monitor cardiac function and morphology in animals receiving pimobendan treatment.
9. Pharmacological research indicates no interaction between pimobendan and the cardiac glycoside ouabain. However, the enhancement of cardiac contractility by pimobendan is diminished when calcium antagonists (e.g., verapamil and diltiazem) and β-antagonists are present.
10. Avoid overdosing. Excessive dosage may result in a positive chronotropic effect or vomiting. In such cases, the dosage should be reduced, and suitable symptomatic treatment commenced.
11. During extended exposure (6 months) at 3 and 5 times the recommended dose in healthy Beagle dogs, mitral valve thickening and left ventricular hypertrophy were observed in some instances. These changes are pharmacodynamically based.
12. Ensure this product is kept out of the reach of children.
13. Thoroughly wash hands after handling the product.
14. If accidental ingestion occurs, seek medical assistance immediately and present the product label or package insert to the healthcare provider. Unintentional ingestion, particularly by a child, may lead to symptoms such as tachycardia, orthostatic hypotension, facial flushing, and headaches.
15. Dispose of any unused veterinary medicinal product or related waste material according to local regulations. Consult local veterinarians for guidance on disposing of these veterinary medicinal products, ensuring compliance with environmental protection standards.